Paul Tudor Jones's UTHR Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 27,567 shares of United Therapeutics Corporation (UTHR) worth $11.56 M, representing 0.02% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in UTHR, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2019, adding 46,222 shares. Largest reduction occurred in Q3 2019, reducing 39,426 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's United Therapeutics Corporation (UTHR) Holding Value Over Time
Track share changes against reported price movement
Quarterly United Therapeutics Corporation (UTHR) Trades by Paul Tudor Jones
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +15,601 | Add 0.00% | 15,600 | $65.83 |
| Q3 2013 | -7,900 | Reduce 50.64% | 7,700 | $78.83 |
| Q4 2013 | -2,600 | Reduce 33.77% | 5,100 | $113.14 |
| Q1 2014 | +4,067 | Add 79.75% | 9,167 | $94.03 |
| Q2 2014 | -999 | Reduce 10.90% | 8,168 | $88.52 |
| Q3 2014 | -5,149 | Reduce 63.04% | 3,019 | $128.52 |
| Q4 2014 | -619 | Reduce 20.50% | 2,400 | $129.58 |
| Q1 2015 | -600 | Reduce 25.00% | 1,800 | $172.22 |
| Q2 2015 | +5,575 | Add 309.72% | 7,375 | $173.97 |
| Q3 2015 | -7,375 | Sold Out | 7,375 | $0.00 |
| Q4 2015 | +2,900 | New Buy | 2,900 | $156.55 |
| Q1 2016 | +1,700 | Add 58.62% | 4,600 | $111.52 |
| Q2 2016 | -900 | Reduce 19.57% | 3,700 | $105.95 |
| Q3 2016 | +6,404 | Add 173.08% | 10,104 | $118.07 |
| Q4 2016 | -6,570 | Reduce 65.02% | 3,534 | $143.46 |
| Q1 2017 | +166 | Add 4.70% | 3,700 | $135.41 |
| Q2 2017 | -3,700 | Sold Out | 3,700 | $0.00 |
| Q3 2017 | +7,777 | New Buy | 7,777 | $117.14 |
| Q4 2017 | -3,692 | Reduce 47.47% | 4,085 | $147.86 |
| Q1 2018 | -4,085 | Sold Out | 4,085 | $0.00 |
| Q2 2018 | +10,706 | New Buy | 10,706 | $113.11 |
| Q3 2018 | +4,616 | Add 43.12% | 15,322 | $127.86 |
| Q4 2018 | -7,604 | Reduce 49.63% | 7,718 | $108.84 |
| Q1 2019 | -7,718 | Sold Out | 7,718 | $0.00 |
| Q2 2019 | +53,940 | New Buy | 53,940 | $78.07 |
| Q3 2019 | -39,426 | Reduce 73.09% | 14,514 | $79.72 |
| Q4 2019 | +21,657 | Add 149.21% | 36,171 | $88.08 |
| Q1 2020 | -36,171 | Sold Out | 36,171 | $0.00 |
| Q2 2020 | +5,672 | New Buy | 5,672 | $120.94 |
| Q3 2020 | -5,672 | Sold Out | 5,672 | $0.00 |
| Q2 2022 | +3,272 | New Buy | 3,272 | $235.64 |
| Q3 2022 | -3,272 | Sold Out | 3,272 | $0.00 |
| Q4 2023 | +20,084 | New Buy | 20,084 | $219.89 |
| Q1 2024 | -20,084 | Sold Out | 20,084 | $0.00 |
| Q3 2024 | +9,346 | New Buy | 9,346 | $358.35 |
| Q4 2024 | +13,041 | Add 139.54% | 22,387 | $352.84 |
| Q1 2025 | -22,387 | Sold Out | 22,387 | $0.00 |
| Q3 2025 | +27,567 | New Buy | 27,567 | $419.21 |
Paul Tudor Jones's United Therapeutics Corporation Investment FAQs
Paul Tudor Jones first purchased United Therapeutics Corporation (UTHR) in Q2 2013, acquiring 15,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held United Therapeutics Corporation (UTHR) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's largest addition to United Therapeutics Corporation (UTHR) was in Q2 2019, adding 53,940 shares worth $4.21 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 27,567 shares of United Therapeutics Corporation (UTHR), valued at approximately $11.56 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, United Therapeutics Corporation (UTHR) represents approximately 0.02% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's peak holding in United Therapeutics Corporation (UTHR) was 53,940 shares, as reported at the end of Q2 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.